Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma

(2019) Shannon M. Matulis et al.   LEUKEMIA

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

(2019) Romain Guièze et al.   CANCER CELL

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells

(2018) Kanika Sharma et al.   Molecular Oncology

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

(2018) Jennifer R. Molina et al.   NATURE MEDICINE

Progressive Upregulation of Oxidative Metabolism Facilitates Plasmablast Differentiation to a T-Independent Antigen

(2018) Madeline J. Price et al.   Cell Reports

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

(2018) Courtney L. Jones et al.   CANCER CELL

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

(2018) Daniel A. Pollyea et al.   NATURE MEDICINE

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death

(2018) Yuxuan Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New Treatment Options for the Management of Multiple Myeloma

(2017) Shaji K. Kumar   Journal of the National Comprehensive Cancer Network

Dual loss of succinate dehydrogenase (SDH) and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors

(2017) Doriane Lorendeau et al.   METABOLIC ENGINEERING

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane

(2016) Katelyn L. O'Neill et al.   GENES & DEVELOPMENT

Isocitrate dehydrogenase mutations in myeloid malignancies

(2016) B C Medeiros et al.   LEUKEMIA

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

(2015) Joan Montero et al.   CELL

Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine

(2015) Lili Guo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

In SilicoModeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy

(2015) Rama K. Mishra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

(2015) S M Matulis et al.   LEUKEMIA

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

(2015) Steven M Chan et al.   NATURE MEDICINE

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

(2015) R Bajpai et al.   ONCOGENE

Ubiquinone-binding site mutagenesis reveals the role of mitochondrial complex II in cell death initiation

(2015) K Kluckova et al.   Cell Death & Disease

Mitochondrial complex II is a source of the reserve respiratory capacity that is regulated by metabolic sensors and promotes cell survival

(2015) J Pfleger et al.   Cell Death & Disease

Curing myeloma at last: defining criteria and providing the evidence

(2014) B. Barlogie et al.   BLOOD

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

(2014) S. Dalva-Aydemir et al.   CLINICAL CANCER RESEARCH

Bcl-xLProtein Protects from C/EBP Homologous Protein (CHOP)-dependent Apoptosis during Plasma Cell Differentiation

(2014) Brian T. Gaudette et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Architecture of mammalian respiratory complex I

(2014) Kutti R. Vinothkumar et al.   NATURE

Improved vectors and genome-wide libraries for CRISPR screening

(2014) Neville E Sanjana et al.   NATURE METHODS

New Roles of Cyclin D1

(2013) Richard G. Pestell   AMERICAN JOURNAL OF PATHOLOGY

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

A bioenergetic profile of non-transformed fibroblasts uncovers a link between death-resistance and enhanced spare respiratory capacity

(2013) Kristen P. Nickens et al.   MITOCHONDRION

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Genome engineering using the CRISPR-Cas9 system

(2013) F Ann Ran et al.   Nature Protocols

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy

(2012) S. K. McBrayer et al.   BLOOD

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction

(2012) G Descamps et al.   BRITISH JOURNAL OF CANCER

ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation

(2012) Guoliang Qing et al.   CANCER CELL

Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells

(2012) Marco Spinazzi et al.   Nature Protocols

SDH mutations in cancer

(2011) Chiara Bardella et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells

(2011) A. A. Morales et al.   BLOOD

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

(2011) T. N. Chonghaile et al.   SCIENCE

CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis

(2010) Sophie C. Cazanave et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation

(2010) Jiangbin Ye et al.   EMBO JOURNAL

Akt Requires Glucose Metabolism to Suppress Puma Expression and Prevent Apoptosis of Leukemic T Cells

(2010) Jonathan L. Coloff et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Succinate dehydrogenase – Assembly, regulation and role in human disease

(2010) Jared Rutter et al.   MITOCHONDRION

BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs

(2010) E. M. Carrington et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Altered mitochondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes

(2010) Michael E. Widlansky et al.   Translational Research

Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells

(2009) Jane L. Armstrong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mimicking the BH3 domain to kill cancer cells

(2009) T Ni Chonghaile et al.   ONCOGENE

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

(2009) Q. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ATF4 is an oxidative stress–inducible, prodeath transcription factor in neurons in vitro and in vivo

(2008) Philipp S. Lange et al.   JOURNAL OF EXPERIMENTAL MEDICINE